BAM
CNCR

Belpointe Asset Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Belpointe Asset Management’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-460
Closed -$6.32K – 3743
2022
Q4 		$6.32K Buy
+460
New +$6.73K ﹤0.01% 2829

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Belpointe Asset Management's CNCR Position: Q1 2023 in Review

Belpointe Asset Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2023, closing a stake of 460 shares — an estimated $6.32K sold.

Belpointe Asset Management first reported a position in CNCR in Q4 2022 and held it in 1 quarter. The position peaked at $6.32K in Q4 2022. 15 funds tracked by Wall St. Rank hold CNCR as of Q1 2023.

  • Belpointe Asset Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 460 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2023, an estimated $6.32K.
  • Belpointe Asset Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2022 and held it in 1 quarter.
  • Belpointe Asset Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $6.32K in Q4 2022.
  • 15 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.